NCT05122260 is a Phase 1 clinical trial of Q-Griffithsin in COVID-19 Prevention, sponsored by Kenneth Palmer.

Who is sponsoring NCT05122260?

NCT05122260 is sponsored by Kenneth Palmer.

What drugs are being tested in NCT05122260?

Interventions in NCT05122260: Q-Griffithsin, Placebo.

What condition does NCT05122260 study?

NCT05122260 studies COVID-19 Prevention.

Is NCT05122260 still recruiting?

NCT05122260 is currently completed. Last updated 29 April 2022.

Last reviewed 2022-04-29 · How we verify

NCT05122260

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

Completed Phase 1 Last updated 29 April 2022

What this trial tests

Phase 1 trial testing Q-Griffithsin in COVID-19 Prevention in 18 participants. Completed in 14 February 2022.

Timeline

11 November 2021

Primary endpoint
27 January 2022

14 February 2022

Quick facts

Lead sponsor	Kenneth Palmer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	18
Start date	11 November 2021
Primary completion	27 January 2022
Estimated completion	14 February 2022
Sites	1 location across United States

Drugs / interventions tested

Q-Griffithsin — full drug profile →
Placebo

Conditions studied

COVID-19 Prevention — all drugs for COVID-19 Prevention →

Sponsor

Kenneth Palmer — full company profile →

Who can join

Adults 18 to 60, any sex, with COVID-19 Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is the first-in-human clinical study to see if a single dose of an investigational nasal spray made from a modified plant protein called Q-Griffithsin is safe, tolerated and acceptable for use by healthy adults 18 to 60 years of age.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Delivery of biologics: Topical administration.
Kulchar RJ, Singh R, Ding S, Alexander E, et al · · 2023 · cited 31× · PMID 37690380 · DOI 10.1016/j.biomaterials.2023.122312
Development and validation of a product acceptability questionnaire for intranasal Q-Griffithsin COVID-19 prophylaxis (SPRAY PAL).
Cash E, Deitz K, Potts KL, Nabeta HW, et al · · 2023 · cited 2× · PMID 37699630 · DOI 10.1136/bmjopen-2023-073735
The Role of ACE2 in SARS-CoV-2 Infection, Pathogenesis, and Antiviral Interventions.
McVoy MA, Kummarapurugu AB. · · 2025 · PMID 41347658 · DOI 10.1002/jmv.70721

Verify or expand the search:

Other trials of Q-Griffithsin

Trials testing the same drug.

NCT05180500 — Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis · Phase 1 · completed

Other Kenneth Palmer trials

Trials by the same sponsor.

NCT05437029 — Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05122260 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kenneth Palmer
Last refreshed: 29 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05122260.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing